The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; GlaxoSmithKline; Histosonics; Incyte; Ipsen; QED Therapeutics; Rafael Pharmaceuticals; SERVIER
Research Funding - Actuate Therapeutics (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
 
Paul Eliezer Oberstein
Consulting or Advisory Role - Amal Therapeutics; Aravive; AstraZeneca; AstraZeneca; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst); Zai Lab (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Smitha S. Krishnamurthi
Research Funding - Aravive (Inst); Bristol-Myers Squibb (Inst); Natera (Inst); Pfizer (Inst)
 
Nashat Y. Gabrail
No Relationships to Disclose
 
Christos Fountzilas
Research Funding - Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
 
Warren S. Brenner
No Relationships to Disclose
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Hongxia Yan
Employment - Aravive
Stock and Other Ownership Interests - Aravive
 
Gail McIntyre
Employment - Aravive
Leadership - Aravive
Stock and Other Ownership Interests - Aravive
 
Charles D. Lopez
Research Funding - Roche/Genentech (Inst); Servier (Inst); Taiho Pharmaceutical (Inst)
 
Niharika B. Mettu
Research Funding - Amgen (Inst); Amphivena (Inst); Aravive (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); ERYTECH Pharma (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Mereo BioPharma (Inst); Repare Therapeutics (Inst); Syros Pharmaceuticals (Inst)
 
Robert B. Geller
Employment - Aravive
Leadership - Aravive
Stock and Other Ownership Interests - Aravive